Success and failure of the cellular immune response against HIV-1

Nature Immunology

Volumn 16, Issue 6, 2015, Pages 563-570

  Migueles, Stephen A ^a   Connors, Mark ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; T LYMPHOCYTE RECEPTOR; EPITOPE; NEF PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXICITY; DNA IMMUNIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; ASYMPTOMATIC DISEASE; DISEASE COURSE; GENETIC POLYMORPHISM; GENETICS; HIV INFECTIONS; HIV SURVIVOR; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; ANTIGENS, VIRAL; ASYMPTOMATIC DISEASES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; EPITOPES, T-LYMPHOCYTE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, GENETIC;

EID: 84929866964     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3161     Document Type: Article

References (116)

1. Migueles, S. A. & Connors, M. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. J. Am. Med. Assoc. 304, 194-201 (2010).
2. Speiser, D. E. et al. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat. Rev. Immunol. 14, 768-774 (2014).
3. Walker, B. D. Elite control of HIV infection: implications for vaccines and treatment. Top. HIV Med. 15, 134-136 (2007).
4. Pereyra, F. et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 200, 984-990 (2009).
5. Hunt, P. W. et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197, 126-133 (2008).
6. Michael, N. L. et al. Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J. Virol. 69, 4228-4236 (1995).
7. Mariani, R. et al. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J. Virol. 70, 7752-7764 (1996).
8. Deacon, N. J. et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988-991 (1995).
9. Blankson, J. N. et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J. Virol. 81, 2508-2518 (2007).
10. Miura, T. et al. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J. Virol. 82, 8422-8430 (2008).
11. Migueles, S. A. et al. The differential ability of HLA B5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences. J. Virol. 77, 6889-6898 (2003).
12. Lamine, A. et al. Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS 21, 1043-1045 (2007).
13. Julg, B. et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin. Infect. Dis. 51, 233-238 (2010).
14. O'Connell, K. A. et al. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J. Virol. 84, 7018-7028 (2010).
15. Mens, H. et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J. Virol. 84, 12971-12981 (2010).
16. Bailey, J. R. et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J. Virol. 82, 7395-7410 (2008).
17. Buckheit, R. W. III et al. Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nat. Commun. 3, 716 (2012).
18. Salgado, M. et al. HLA-B57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J. Virol. 88, 3340-3352 (2014).
19. Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 1856-1862 (1996).
20. Cohen, O. J. et al. CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32. J. Virol. 72, 6215-6217 (1998).
21. Martin, M. P. et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39, 733-740 (2007).
22. Migueles, S. A. et al. HLA B5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. USA 97, 2709-2714 (2000).
23. Lambotte, O. et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41, 1053-1056 (2005).
24. Kloosterboer, N. et al. Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus. Virology 339, 70-80 (2005).
25. Sáez-Cirión, A. et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. USA 104, 6776-6781 (2007).
26. Han, Y. et al. The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS 22, 541-544 (2008).
27. Pereyra, F. et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197, 563-571 (2008).
28. Migueles, S. A. et al. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 83, 11876-11889 (2009).
29. Walker, B. D. & Yu, X. G. Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 13, 487-498 (2013).
30. Kaech, S. M. & Ahmed, R. Immunology. CD8 T cells remember with a little help. Science 300, 263-265 (2003).
31. Iyasere, C. et al. Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. J. Virol. 77, 10900-10909 (2003).
32. Emu, B. et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J. Virol. 79, 14169-14178 (2005).
33. Kaufmann, D. E. et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8, 1246-1254 (2007).
34. Potter, S. J. et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81, 13904-13915 (2007).
35. Tilton, J. C. et al. Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. J. Virol. 81, 2713-2725 (2007).
36. Owen, R. E. et al. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS 24, 1095-1105 (2010).
37. Ferre, A. L. et al. HIV controllers with HLA-DRB113 and HLA-DQB106 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J. Virol. 84, 11020-11029 (2010).
38. Soghoian, D. Z. et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med. 4, 123ra125 (2012).
39. Loffredo, J. T. et al. Mamu-B08-positive macaques control simian immunodeficiency virus replication. J. Virol. 81, 8827-8832 (2007).
40. Yant, L. J. et al. The high-frequency major histocompatibility complex class I allele Mamu-B17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 80, 5074-5077 (2006).
41. Schmitz, J. E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857-860 (1999).
42. Jin, X. et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
43. Friedrich, T. C. et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 81, 3465-3476 (2007).
44. Hersperger, A. R. , Migueles, S. A. , Betts, M. R. & Connors, M. Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr. Opin. HIV AIDS 6, 169-173 (2011).
45. Draenert, R. et al. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J. Virol. 78, 630-641 (2004).
46. Nou, E. , Zhou, Y. , Nou, D. D. & Blankson, J. N. Effective downregulation of HLA-A2 and HLA-B57 by primary human immunodeficiency virus type 1 isolates cultured from elite suppressors. J. Virol. 83, 6941-6946 (2009).
47. Goulder, P. J. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3, 212-217 (1997).
48. Goulder, P. J. et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412, 334-338 (2001).
49. Kelleher, A. D. et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med. 193, 375-386 (2001).
50. Brockman, M. A. et al. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J. Virol. 81, 12608-12618 (2007).
51. Bailey, J. R. , Williams, T. M. , Siliciano, R. F. & Blankson, J. N. Maintenance of viral suppression in HIV-1-infected HLA-B57+ elite suppressors despite CTL escape mutations. J. Exp. Med. 203, 1357-1369 (2006).
52. Miura, T. et al. HLA-B57/B5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphotye recognition. J. Virol. 83, 2743-2755 (2009).
53. Miura, T. et al. HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J. Virol. 83, 3407-3412 (2009).
54. Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381-385 (2015).
55. Pereyra, F. et al. HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes. J. Virol. 88, 12937-12948 (2014).
56. Migueles, S. A. et al. CD8+ T-cell cytotoxic capacity associated with human immunodeficiency virus-1 control can be mediated through various epitopes and human leukocyte antigen types. EBioMedicine 2, 46-58 (2015).
57. Hamann, D. et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186, 1407-1418 (1997).
58. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109-1118 (1994).
59. Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106-111 (2001).
60. van Lier, R. A. , ten Berge, I. J. & Gamadia, L. E. Human CD8(+) T-cell differentiation in response to viruses. Nat. Rev. Immunol. 3, 931-939 (2003).
61. Appay, V. et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192, 63-75 (2000).
62. van Baarle, D. , Kostense, S. , van Oers, M. H. , Hamann, D. & Miedema, F. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol. 23, 586-591 (2002).
63. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
64. Petrovas, C. et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 203, 2281-2292 (2006).
65. Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202 (2006).
66. Paiardini, M. et al. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J. Immunol. 174, 2900-2909 (2005).
67. Lécuroux, C. et al. Both HLA-B57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. J. Virol. 88, 176-187 (2014).
68. Callan, M. F. et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402 (1998).
69. Faint, J. M. et al. Memory T cells constitute a subset of the human CD8+CD45RA+ pool with distinct phenotypic and migratory characteristics. J. Immunol. 167, 212-220 (2001).
70. Wherry, E. J. et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4, 225-234 (2003).
71. Marzo, A. L. et al. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat. Immunol. 6, 793-799 (2005).
72. Jagannathan, P. et al. Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J. Virol. 83, 2728-2742 (2009).
73. Migueles, S. A. et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3, 1061-1068 (2002).
74. Sandberg, J. K. , Fast, N. M. & Nixon, D. F. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J. Immunol. 167, 181-187 (2001).
75. Ochsenbein, A. F. et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J. Exp. Med. 200, 1407-1417 (2004).
76. Migueles, S. A. et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29, 1009-1021 (2008).
77. Almeida, J. R. et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204, 2473-2485 (2007).
78. Almeida, J. R. et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 113, 6351-6360 (2009).
79. Berger, C. T. et al. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J. Virol. 85, 9334-9345 (2011).
80. Mothe, B. et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J. Transl. Med. 9, 208 (2011).
81. Mothe, B. et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One 7, e29717 (2012).
82. Viganò, S. et al. Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells. PLoS Pathog. 9, e1003423 (2013).
83. Chen, H. et al. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat. Immunol. 13, 691-700 (2012).
84. Iglesias, M. C. et al. Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood 118, 2138-2149 (2011).
85. Price, D. A. et al. Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J. Exp. Med. 206, 923-936 (2009).
86. Mendoza, D. et al. HLA B5701-positive long-term nonprogressors/elite controllers are not distinguished from progressors by the clonal composition of HIV-specific CD8+ T cells. J. Virol. 86, 4014-4018 (2012).
87. Betts, M. R. et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107, 4781-4789 (2006).
88. Zimmerli, S. C. et al. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc. Natl. Acad. Sci. USA 102, 7239-7244 (2005).
89. Ferre, A. L. et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113, 3978-3989 (2009).
90. Sáez-Cirión, A. et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182, 7828-7837 (2009).
91. de Quiros, J. C. et al. Resistance to replication of human immunodeficiency virus challenge in SCID-Hu mice engrafted with peripheral blood mononuclear cells of nonprogressors is mediated by CD8(+) T cells and associated with a proliferative response to p24 antigen. J. Virol. 74, 2023-2028 (2000).
92. Yang, H. et al. Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J. Infect. Dis. 206, 552-561 (2012).
93. Hersperger, A. R. et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 6, e1000917 (2010).
94. Fellay, J. et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317, 944-947 (2007).
95. Dalmasso, C. et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One 3, e3907 (2008).
96. Pereyra, F. et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551-1557 (2010).
97. Pelak, K. et al. Host determinants of HIV-1 control in African Americans. J. Infect. Dis. 201, 1141-1149 (2010).
98. Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).
99. Lifson, J. D. et al. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J. Virol. 75, 10187-10199 (2001).
100. Haigwood, N. L. et al. Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile. Immunol. Lett. 51, 107-114 (1996).
101. Lifson, J. D. et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74, 2584-2593 (2000).
102. Altfeld, M. et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17, 2581-2591 (2003).
103. Horton, H. et al. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J. Immunol. 177, 7406-7415 (2006).
104. Kaslow, R. A. et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J. Virol. 75, 8681-8689 (2001).
105. Migueles, S. A. et al. Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog. 7, e1002002 (2011).
106. Miura, T. et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J. Virol. 84, 7581-7591 (2010).
107. Yue, L. et al. Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. PLoS Pathog. 11, e1004565 (2015).
108. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
109. Gray, G. E. et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis. 11, 507-515 (2011).
110. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
111. McElrath, M. J. et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372, 1894-1905 (2008).
112. Tan, W. G. et al. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J. Virol. 87, 1359-1372 (2013).
113. Hansen, S. G. et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15, 293-299 (2009).
114. Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
115. Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013).
116. Hansen, S. G. et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340, 1237874 (2013).